BETA GALACTOCEREBROSIDASE (KRABBE)

Beta Galactocerebrosidase (Krabbe) is a specialized enzyme test used to measure the activity of galactocerebrosidase, also known as galactosylceramidase or GALC. This lysosomal enzyme helps break down certain fats found in the protective myelin covering of nerve cells.

Markedly reduced GALC enzyme activity may support a diagnosis of Krabbe disease, also called globoid cell leukodystrophy. Krabbe disease is a rare inherited lysosomal storage disorder caused by disease-causing variants in the GALC gene. Enzyme results must be interpreted with clinical findings and are generally confirmed using molecular genetic testing and other specialized investigations.

Benefits of the Test

• Measures galactocerebrosidase enzyme activity.
• Supports evaluation of suspected Krabbe disease.
• Helps identify GALC enzyme deficiency.
• Supports investigation of progressive neurological symptoms.
• May be used following an abnormal newborn-screening result.
• Helps guide molecular genetic confirmation.
• Supports family counselling and specialist referral.
• May enable earlier evaluation for time-sensitive treatment options.

Why Doctors Recommend This Test

Doctors may recommend this test for infants or children with irritability, feeding difficulties, developmental regression, abnormal muscle stiffness, weakness, seizures, vision loss, hearing impairment, or progressive neurological deterioration. It may also be advised following an abnormal newborn-screening result, for people with later-onset neurological symptoms, or when there is a family history of Krabbe disease.

Preparation Before Test

• No fasting is generally required unless specifically advised.
• The required specimen may be blood, dried blood spot, or isolated white blood cells depending on the laboratory protocol.
• Use the collection tube or card specified by the testing laboratory.
• Inform the doctor about recent blood transfusions or stem-cell transplantation.
• Share details of neurological symptoms and developmental history.
• Provide newborn-screening, enzyme, imaging, and genetic reports if available.
• The specimen must be stored and transported under the specified conditions.
• Follow all collection and handling instructions carefully because enzyme activity can be affected by an unsuitable specimen.

Normal Reporting Time

Most Beta Galactocerebrosidase (Krabbe) reports at Focus Diagnostics are initiated within 2–3 hours of specimen receipt for verification, processing, and specialized enzyme-testing workflow preparation. Because this is a specialized lysosomal enzyme assay, final analysis, validation, quality review, and reporting may require several working days depending on laboratory schedules and testing protocols.

Who Should Take This Test?

This test may be recommended for:

• Infants with symptoms suggestive of Krabbe disease.
• Children with developmental regression or progressive neurological deterioration.
• Patients with unexplained loss of motor abilities.
• Individuals with abnormal muscle tone, seizures, or vision impairment.
• Newborns with an abnormal Krabbe disease screening result.
• People with a family history of confirmed GALC-related disease.
• Individuals with possible juvenile or adult-onset Krabbe disease.
• Patients advised to undergo testing by a neurologist, geneticist, or metabolic specialist.

Detailed Information

Lysosomes are cellular structures containing enzymes that break down complex substances. Galactocerebrosidase is a lysosomal enzyme involved in degrading galactosylceramide and psychosine, lipids associated with myelin-producing cells.

Myelin is the protective covering surrounding nerve fibres in the brain, spinal cord, and peripheral nerves. It allows electrical signals to travel efficiently through the nervous system. Healthy GALC activity is important for maintaining normal myelin metabolism.

Krabbe disease develops when pathogenic variants in the GALC gene cause deficient galactocerebrosidase activity. The condition follows an autosomal-recessive inheritance pattern, meaning an affected person usually inherits one altered gene copy from each parent.

When GALC activity is severely reduced, psychosine accumulates and damages cells responsible for producing and maintaining myelin. Progressive loss of myelin disrupts communication within the central and peripheral nervous systems.

The infantile form commonly begins during the first months of life. Symptoms may include irritability, feeding difficulty, unexplained crying, sensitivity to stimulation, stiffness, weakness, developmental regression, seizures, vision loss, and progressive loss of motor function.

Juvenile and adult-onset forms may progress more slowly. Symptoms can include weakness, walking difficulty, changes in muscle tone, vision problems, loss of coordination, cognitive changes, and peripheral neuropathy.

Low GALC activity supports the possibility of Krabbe disease but does not independently establish the diagnosis or accurately predict when symptoms will begin. Some individuals may have low measured activity because of benign genetic variants known as pseudodeficiency alleles.

Additional investigations may include GALC gene analysis, psychosine measurement, neurological examination, brain MRI, nerve-conduction studies, eye assessment, hearing evaluation, and other metabolic or genetic tests.

Psychosine measurement may help distinguish affected individuals from those with pseudodeficiency and may contribute to risk assessment following an abnormal newborn screen. Final interpretation should be performed by specialists experienced in lysosomal storage disorders.

Carrier detection generally requires molecular genetic testing because enzyme activity may overlap between carriers and unaffected individuals. Once causative familial variants are known, targeted testing may support family screening, reproductive counselling, and prenatal assessment.

Early diagnosis is especially important in infants because hematopoietic stem-cell transplantation may provide the greatest benefit when performed before significant neurological symptoms develop. Treatment suitability and timing must be determined by a specialist centre.

At Focus Diagnostics, Beta Galactocerebrosidase testing is performed using validated enzyme-assay methodologies, controlled specimen-processing procedures, and stringent quality assurance standards to provide accurate, reliable, and clinically meaningful results.